Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.195 -0.035 (-2.85%)

Streaming Delayed Price Updated: 10:33 AM EST, Feb 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	194,077
Open	1.230
Bid (Size)	1.190 (1,500)
Ask (Size)	1.200 (4,400)
Prev. Close	1.230
Today's Range	1.180 - 1.230
52wk Range	0.6611 - 1.940
Shares Outstanding	98,384,456
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

January 23, 2026

Issued on behalf of Avant Technologies Inc.

From Equity Insider

Via GlobeNewswire

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

December 08, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+21.1%	+21.1%
1 Month	+18.3%	+18.3%
3 Month	-5.2%	-5.2%
6 Month	+12.7%	+12.7%
1 Year	-5.9%	-5.9%

More News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

November 13, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 04, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

October 26, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Via MarketMinute

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

October 14, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

August 25, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss ↗

August 12, 2025

Via Chartmill

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

August 12, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

August 05, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

June 11, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

4 Analysts Assess Fate Therapeutics: What You Need To Know ↗

May 14, 2025

Via Benzinga

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

April 29, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Gapping stocks in Monday's session ↗

April 14, 2025

Via Chartmill

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fate Therapeutics, Inc. - Common Stock trade on?

Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?

The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market

What is the current price of Fate Therapeutics, Inc. - Common Stock?

The current price of Fate Therapeutics, Inc. - Common Stock is 1.195

When was Fate Therapeutics, Inc. - Common Stock last traded?

The last trade of Fate Therapeutics, Inc. - Common Stock was at 02/03/26 10:33 AM ET

What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?

The market capitalization of Fate Therapeutics, Inc. - Common Stock is 117.57M

How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?

Fate Therapeutics, Inc. - Common Stock has 118M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.